A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Br J Cancer · 2023 · PMC10006169 · PMID 36624219

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

MAPK pathway activity as measured by DUSP6 expression showed a trend towards suppression in the PR group (Supplementary Fig. 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.